Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | GCG | P01275 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | GIPR | P48546 | 2/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653731 | 0.92 | HAO1 (0.46) | GCGREPHX2HAO1CYP2D6APAF1 | |
| SCHEMBL2654474 | 0.87 | HAO1 (0.42) | GCGREPHX2HAO1CYP2D6APAF1 | |
| SCHEMBL2647125 | 0.87 | CYP2D6 (0.45) | GCGRGCGHAO1CYP2D6APAF1 | |
| SCHEMBL2660182 | 0.86 | GCGR (0.45) | GCGRGCGHAO1CYP2D6APAF1 | |
| SCHEMBL2647568 | 0.86 | GCGR (0.45) | GCGRGCGHAO1CYP2D6APAF1 | |
| SCHEMBL2646694 | 0.86 | GCGR (0.49) | GCGRHAO1CYP2D6APAF1 | |
| SCHEMBL6756859 | 0.86 | GCGR (0.49) | GCGRHAO1CYP2D6APAF1 | |
| SCHEMBL6755406 | 0.86 | GCGR (0.49) | GCGRHAO1CYP2D6APAF1 | |
| SCHEMBL2653410 | 0.85 | CYP2D6 (0.44) | GCGREPHX2GCGHAO1CYP2D6 | |
| SCHEMBL2647801 | 0.84 | GCGR (0.46) | GCGRGCGHAO1CYP2D6APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463715-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | GCGR 4/4885EPHX2 4354/4885ADRB3 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.